Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Lewis, Daniel J.; Rook, Alain H.
  • Source:
    Expert Review of Anticancer Therapy (EXPERT REV ANTICANCER THER), Jun2020; 20(6): 447-452. (6p)
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Affiliation:
      Cutaneous Oncology Fellow, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
      Professor of Dermatology and Director of Cutaneous Lymphoma Program, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    • Abstract:
      Introduction: Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T-cell lymphoma characterized by a poor prognosis. Treatments are associated with high rates of relapse, and thus there exists an unmet medical need for new, improved therapies. Mogamulizumab is a novel defucosylated monoclonal antibody targeting C-C chemokine receptor 4 that eradicates malignant cells via antibody-dependent cellular cytotoxicity (ADCC).Areas Covered: Phase I-III clinical trials involving mogamulizumab demonstrated its significant efficacy and tolerability. In the phase III MAVORIC study, mogamulizumab exhibited greater efficacy than vorinostat (response rate, 28% versus 5%; median progression-free survival, 7.7 versus 3.1 months, respectively) for advanced, relapsed/refractory MF/SS. Responses were durable (median, 14.1 months), and response rates were highest in SS (37%) and within the blood compartment (68%). Common adverse events include infusion reactions and drug eruptions. The drug also increases the risk of immune-mediated complications such as autoimmune disease and acute graft-versus-host disease following transplantation.Expert Opinion: Mogamulizumab represents a valuable therapy for advanced MF/SS as it can produce prolonged responses, particularly within the peripheral blood. Since it eliminates malignant T cells via ADCC, combining mogamulizumab with immunotherapeutic agents such as interferons, interleukin-12, and Toll-like receptor agonists may further enhance its efficacy.
    • Journal Subset:
      Biomedical; Europe; UK & Ireland
    • ISSN:
      1473-7140
    • MEDLINE Info:
      PMID: NLM32320304 NLM UID: 101123358
    • Publication Date:
      In Process
    • Publication Date:
      20200721
    • DOI:
      http://dx.doi.org/10.1080/14737140.2020.1760096
    • Accession Number:
      144635957
  • Citations
    • ABNT:
      LEWIS, D. J.; ROOK, A. H. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Review of Anticancer Therapy, [s. l.], v. 20, n. 6, p. 447–452, 2020. DOI 10.1080/14737140.2020.1760096. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=144635957. Acesso em: 23 set. 2020.
    • AMA:
      Lewis DJ, Rook AH. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Review of Anticancer Therapy. 2020;20(6):447-452. doi:10.1080/14737140.2020.1760096
    • APA:
      Lewis, D. J., & Rook, A. H. (2020). Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Review of Anticancer Therapy, 20(6), 447–452. https://doi.org/10.1080/14737140.2020.1760096
    • Chicago/Turabian: Author-Date:
      Lewis, Daniel J., and Alain H. Rook. 2020. “Mogamulizumab in the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome: Safety and Efficacy.” Expert Review of Anticancer Therapy 20 (6): 447–52. doi:10.1080/14737140.2020.1760096.
    • Harvard:
      Lewis, D. J. and Rook, A. H. (2020) ‘Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy’, Expert Review of Anticancer Therapy, 20(6), pp. 447–452. doi: 10.1080/14737140.2020.1760096.
    • Harvard: Australian:
      Lewis, DJ & Rook, AH 2020, ‘Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy’, Expert Review of Anticancer Therapy, vol. 20, no. 6, pp. 447–452, viewed 23 September 2020, .
    • MLA:
      Lewis, Daniel J., and Alain H. Rook. “Mogamulizumab in the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome: Safety and Efficacy.” Expert Review of Anticancer Therapy, vol. 20, no. 6, June 2020, pp. 447–452. EBSCOhost, doi:10.1080/14737140.2020.1760096.
    • Chicago/Turabian: Humanities:
      Lewis, Daniel J., and Alain H. Rook. “Mogamulizumab in the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome: Safety and Efficacy.” Expert Review of Anticancer Therapy 20, no. 6 (June 2020): 447–52. doi:10.1080/14737140.2020.1760096.
    • Vancouver/ICMJE:
      Lewis DJ, Rook AH. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy. Expert Review of Anticancer Therapy [Internet]. 2020 Jun [cited 2020 Sep 23];20(6):447–52. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=144635957